×
ADVERTISEMENT

FEBRUARY 20, 2025

Amneal Launches Mesalamine and Receives FDA Approval for Lenalidomide

  • Mesalamine 800-mg delayed-release tablets, referencing Asacol HD
  • Lenalidomide capsules, referencing Revlimid

Amneal Pharmaceuticals Inc., a global biopharmaceutical company, today announced the launch of mesalamine 800-mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults. The company also received approval from the FDA for its Abbreviated New Drug Application for lenalidomide capsules in 2.5-, 5-, 10-, 15-, 20- and 25-mg